What Contributes to Quality of Life in Patients with Parkinson's Disease?
JNNP 69:308-312,289, Schrag,A. et al, 2000
Efficacy, Safety, and Tolerance of the Non-Ergoline Dopamine Agonist Pramipexole in the Treatment of Advanced Parkinson's Disease:A Double Blind, Placebo Controlled, Randomised, Multicentre Study
JNNP 66:436-441, Pinter,M.M.,et al, 1999
Comparative Effects of Unilateral and Bilateral Subthalamic Nucleus Deep Brain Stimulation
Neurol 53:561-566, Kumar,R.,et al, 1999
Assessment of Motor Function After Stereotactic Pallidotomy
Neurol 50:266-270, Ondo,W.G.,et al, 1998
Double-Blind Evaluation of Subthalamic Nucleus Deep Brain Stimulation in Advanced Parkinson's Disease
Neurol 51:850-855, Kumar,R.,et al, 1998
Treatment of Advanced Parkinson's Disease by Posterior GPi Pallidotomy:1-Year Results of a Pilot Study
Ann Neurol 40:355-366, 3411996., Baron,M.S.,et al, 1996
Unilateral Transpl of Human Fetal Mesencephalic Tissue Into the Caudate Nucleus of Pts with Parkinson's
NEJM 327:1541-1548, Spencer,D.D.,et al, 1992
Survival of Implanted Fetal Dopamine Cells & Neuro Improvement 12 to 46 Months after Transpl for Parkinson's
NEJM 327:1549-1555, 15891992., Freed,C.R.,et al, 1992
Bilateral Fetal Mesencephalic Grafting in Two Patients with Parkinsonism Induced by MPTP
NEJM 327:1556-1563, 15891992., Widner,H.,et al, 1992
Does Ageing Aggravate Parkinsonisn Disability?
JNNP 54:780-782, Blin,J.,et al, 1991
Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
Invited Article: Changing Concepts in Parkinson Disease: Moving Beyond the Decade of the Brain
Neurol 70:1996-2003, Marras,C. &Lang,A., 2008
Cardiac Valve Regurgitation With Pergolide Compared With Nonergot Agonsits in Parkinson Disease
Arch Neurol 64:377-380, Dewey,R.B.,Jr, et al, 2007
Risk Factors for the Development of Pedal Edema in Patients Using Pramipexole
Arch Neurol 64:820-824, Kleiner-Fisman,G. &Fisman,D.N., 2007
Pathological Gambling Associated with Dopamine Agonist Therapy in Parkinson's
Neurol 61:422-423, Driver-Dunckley,E.,et al, 2003
Objective Changes in Motor Function During Placebo Treatment in PD
Neurol 54:710-714, Goetz,C.G.,et al, 2000
Practice Styles of US Compared to UK Neurologists
Neurol 50:1661-1668, Vickrey,B.G.,et al, 1998
Neuropsychological Consequences of Posteroventral Pallidotomy for the Treatment of Parkinson's Disease
Neurol 51:207-215, Trepanier,L.L.,et al, 1998
Cognitive Functioning After Pallidotomy for Refractory Parkinson's Disease
JNNP 65:150-154, 1481998., Perrine,K.,et al, 1998
Parkinson's Disease
JNNP 57:672-681, Marsden,C.D., 1994
Drug-Induced Alzheimerism
Arch Neurol 45:356-357, Kurlan,R.&Como,P., 1988
Update on Parkinson Disease
NY State J Med, 87:147-1531987., Lieberman,A.N., 1987
Considerations in the Management of Parkinsonism
Neurol 28:5, Fahn,S.,et al, 1978